🔎 Trials Near Me

Home › Breast Cancer › NCT07076147

Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer

RecruitingObservational studyHealthy volunteers welcome

Who can join

Ages 30 to 75 · Women · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* \* \>= 30 years

  * =\< 75 years
  * Women with either:

    * Genetic test results showing moderately increased breast cancer risk due to a pathogenic/likely pathogenic variant in ATM, CHEK2, BARD1, RAD51C, or RAD51D (Mutation carrier group) OR
    * Calculated lifetime breast cancer risk estimates between 20% and 40% according to the Tyrer-Cuzick V8.0B empiric risk model (Empiric risk group)
  * Patients provided breast cancer risk assessments by genetic counselors at USC Norris or LA General Hospital beginning in 2021 and at least 12 months ago
  * Women recommended to undergo annual breast MRI and/or annual mammogram beginning at the time of their genetic counseling risk assessment
  * English or Spanish speaking patients

Exclusion Criteria:

* \* History of breast cancer before genetic counseling at University of Southern California (USC)

  * Any metastatic cancer diagnosis at time of genetic counseling risk assessment
  * Deceased
  * Patient underwent a risk reducing mastectomy before their genetic counseling risk assessment

About the study

This study assesses breast cancer screening adherence for women at moderately increased risk for developing breast cancer based on gene mutation status or empiric risk model estimates. It also seeks to determine facilitators and barriers to screening.

What is being tested

Sponsor: University of Southern California · Participants: 150 · Started: Jun 2, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07076147

Locations in the U.S.

CaliforniaLos Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.